The workshop will explore the advantages and challenges of both liquid and powder nasal formulations, focusing on methods to enhance stability and retention in the nasal cavity. It will also discuss optimal device selection for preclinical and clinical trials using advanced predictive tools like nasal casts.
Furthermore, the event will offer insights into effective manufacturing strategies for clinical trials involving nasally administered biologics.
It is tailored for professionals in fields such as research and development, formulation and clinical development, CMC management, program management, development engineering, and clinical trial manufacturing. Attendees will leave with a robust understanding of the nuances of nasal drug delivery, equipped with insights into overcoming barriers of cellular penetration and absorption, and recognizing ideal target product profiles.
Dr. Julie Suman, Vice President of Scientific Affairs at Aptar Pharma, expressed enthusiasm about the partnership with IPI, stating, “We are excited to continue our educational workshops with the IPI and our experts are keen to share critical insights into the specific challenges and strategies in delivering biologics through the nasal pathway.”
These educational workshops are open to all pharmaceutical professionals with an interest in the intricacies of nasal drug delivery.
REGISTER TO WORKSHOP ‘’Nasal Biologics and Drug Delivery’’
Our panel of speakers is shown below:
- Dr Julie Suman, Vice President Scientific Affairs, Aptar Pharma
- Dave Farrow, Director of Science and Technology, Aptar Pharma
- Lucas Silva, Senior Specialist in Analytical Development at Nanopharm, an Aptar Pharma company
- Gemma Budd, General Manager at Nanopharm, an Aptar Pharma company
